ReviewClinical, cosmetic and investigational dermatology2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.
Review in Clinical, cosmetic and investigational dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris.Archives of dermatological research · 2024Pooled it
- The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2023Pooled it
- Bloodletting cupping combined with conventional measures therapy for psoriasis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2023Pooled it
- The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.Nature communications · 2024Trial
- Trial
- Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis.International journal of dermatology · 2026Article
- Adaptive immune dysregulation drives new-onset refractory status epilepticus.Frontiers in immunology · 2026Review
- Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country.Dermatology and therapy · 2026Article
- Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe.Rheumatology and therapy · 2025Article
- Biologics and Small-Molecule Therapies in Netherton Syndrome: A Comprehensive Review.The Journal of dermatology · 2025Review
- Management of Challenging Psoriasis Clinical Scenarios.Dermatology and therapy · 2025Article
- Tapinarof Nanogels as a Promising Therapeutic Approach.Pharmaceutics · 2025Review
- Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use.Life (Basel, Switzerland) · 2025Article
- Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains-Should Psychosocial Life Impairment Be Considered a Comorbidity?Journal of clinical medicine · 2025Article
- Anti-Psoriatic Efficacies of Psorogrit and Divya-Taila, in Murine Models of Imiquimod and TPA-Induced Psoriasis-Like Inflammation are Driven by Modulation in IL-17RA/IL-23 and IL-8/TNF-α Signaling Axes.Journal of inflammation research · 2025Article
- Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.Psoriasis (Auckland, N.Z.) · 2025Article
- Improvement in Patient-reported Symptoms and Satisfaction with Tildrakizumab in a Real-world Study in Patients with Moderate-to-severe Plaque Psoriasis.The Journal of clinical and aesthetic dermatology · 2024Article
- Applications of Biological Therapy for Latent Infections: Benefits and Risks.International journal of molecular sciences · 2024Review
- Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real-life data are important to improve the dermatological decision-making process, including patients who are typically excluded from clinical trials, such as subjects suffering from several comorbidities, subjects on polypharmacy, as well as multifailure patients. Herein, we performed a comprehensive literature review about real-life data available on guselkumab, risankizumab, and tildrakizumab. Real-life data of anti-IL-23 seem to confirm the promising results of IL-23 shown by clinical trials, highlighting the efficacy and safety profiles of this new class of biologics also in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.